Depression and Anxiety Trial, Not Yet Recruiting NCT06851741 Sponsor: NHS Greater Glasgow and Clyde Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Not Yet Recruiting

NCT06851741
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • The person has a severe or profound learning disability, confirmed by a carer completing a standardised assessment called the Vineland Adaptive Behaviour Scales (3rd edition), with a score of 50 or below — this typically means the person has high support needs, limited or no ability to speak or understand speech, and significant difficulties with everyday living skills.
  • The person is 18 years old or older.
  • The person has been diagnosed with clinically significant depression (without manic episodes), assessed using diagnostic guidelines specifically designed for adults with learning disabilities.
  • The person has a family member or paid carer who has supported them for at least 6 months and is able to attend the screening and baseline visits, or who can provide information about the person covering the 4 months before the trial begins — this carer (or another named person) should be available for weekly or fortnightly sessions with a practitioner and currently provides at least 10 hours of support per week to the person.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • The person has a mild or moderate learning disability (rather than severe or profound).
  • The person has a condition or presentation that the research team judges would likely make it difficult to engage with the treatment — for example, severe agitation, late-stage dementia, or epilepsy that is not well controlled.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0141 330 4988

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
NHS Greater Glasgow and Clyde
Registry
ClinicalTrials.gov
Start date
4 March 2025
Est. completion
1 September 2026

Primary endpoints

Intellectual Disabilities Depression Scale (IDDS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov